Alison Liou

Alison Liou is a senior associate in Goodwin’s Technology & Life Sciences group and a member of the firm’s Intellectual Property Transactions and Strategies practice. 

Alison represents public and private biotechnology, pharmaceutical, diagnostic, medical device, and other life sciences companies, as well as research institutions, in complex collaboration, co-development, licensing, commercial, M&A, financing, and other intellectual property and strategic transactions. 

Prior to joining Goodwin, Alison was an associate in Ropes & Gray’s intellectual property transactions and life sciences groups, during which she completed a secondment at The Broad Institute of MIT and Harvard. Alison also has experience as the director of business development at a venture-backed growth-stage biotechnology company and experience in biochemistry research at global research institutions, including at Massachusetts General Hospital.

Representative Matters:

• Orum Therapeutics in its license and option agreement with Vertex to develop novel degrader-antibody conjugates, for an upfront payment of $15 million and up to $310 million per target in option and milestone payments for up to three targets, plus tiered royalties
• R-Bridge Healthcare Fund, an affiliate of CBC Group, in its $38 million investment in royalties payable to Santhera Pharmaceuticals on sales of AGAMREE in North America and Greater China
• Kymera Therapeutics in its collaboration with NEOsphere Biotechnologies to discover novel molecular glue targets, for an upfront payment and success-based milestone payments
• Repertoire Immune Medicines in its strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases, for an upfront payment of $65 million and up to $1.8 billion in development, regulatory, and commercial milestone payments plus tiered royalties  
• An American multinational, pharmaceutical, and medical technologies corporation in its strategic collaboration with Odyssey Therapeutics to advance AI-driven small molecule drug discovery
• AVROBIO in its combination with Tectonic Therapeutic in an all-stock transaction
• Prolaio in its acquisition of PhysIQ to enhance its cardiovascular care platform
• Alkermes in its completed separation of its oncology business into Mural Oncology
• Intellia Therapeutics in its expanded research collaboration with Regeneron Pharmaceuticals to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases
• Aclipse Therapeutics in its exclusive, worldwide license agreement with Chong Kun Dang Pharmaceutical Corporation to develop potential disease-modifying treatments for gastroparesis
• Korro Bio on its merger with Frequency Therapeutics in an all-stock transaction
• Surface Oncology on its acquisition by Coherus in stock for stock transaction valued at up to $65 million plus contingent value rights
• Tubulis in its strategic license agreement with Bristol Myers Squibb to develop differentiated antibody-drug conjugates (ADCs) for cancer, for an upfront payment of $22.75 million and up to $1 billion in development, regulatory, and commercial milestone payments plus royalties
• Mercy BioAnalytics on its $41 million Series A financing
• Gladstone Institutes in connection with licensing and collaboration agreements
• A private biotechnology company in its strategic collaboration agreement with a collaboration partner
• Licensing of intellectual property assets from research institutions
• A public global biopharmaceutical company in its exclusive worldwide option and license agreement with a public immunotherapy company for a costimulation antagonist for autoimmune and inflammatory diseases*
• A public global biotechnology company in its strategic collaboration agreement with a public leading gene editing company to develop gene editing therapies for muscular dystrophies*
• A public global biotechnology company in its strategic collaboration agreement with a venture-backed biotechnology company to develop novel AAV capsids for genetic therapies*
• A public commercial-stage oncology company in its exclusive license agreement with a public Chinese pharmaceutical company to develop and commercialize its lead oncology compound in Greater China*
• A public biotechnology company in its strategic collaboration agreement with a venture-backed biopharmaceutical company to develop antibiotics for drug-resistant infections*
• A public biopharmaceutical company in its collaboration agreement with an antibody discovery company to develop antibody-based therapeutics*
• A leading university and a leading hospital in their research collaboration agreements with a healthcare investment firm to develop new therapies*
• A leading academic research institute in its collaboration and license agreements relating to its gene editing technologies*

* Denotes experience prior to joining Goodwin

Alison represents the Children’s Tumor Foundation in its collaborations to drive research, expand knowledge, and advance care for the neurofibromatosis community. Representative matters:

• Children’s Tumor Foundation in its investment in Healx to advance Neurofibromatosis Type 1 treatments
• Children’s Tumor Foundation in a collaboration agreement with the Global Coalition for Adaptive Research to accelerate the development of treatments for patients with neurofibromatosis (NF)

Alison is a member of the Boston Bar Association.

• Leadership Council on Legal Diversity (LCLD) 1L Scholar, Class of 2015